{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-016871","form_type":"8-K","ticker":"FBIO","cik":"0001429260","company_name":"Fortress Biotech, Inc.","filed_at":"2023-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.044861+00:00","generated_at":"2026-06-09T08:22:22.357579+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Fortress Biotech regains Nasdaq compliance; Sentynl takes over CUTX-101 development","bullets":["Nasdaq notified Fortress on Oct 24, 2023 of compliance with $1.00 bid price requirement; listing matter closed.","Sentynl elected Approval Deadline Transfer for CUTX-101 after NDA not approved by Sep 30, 2023; closing expected Nov 2023.","Cyprium retains up to $133.5M in milestones, tiered royalties (3%–12.5%), and any priority review voucher.","Transfer expected to reduce Cyprium's development spending on CUTX-101."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-016871","json":"https://secwatch.observer/filing/0001558370-23-016871.json","markdown":"https://secwatch.observer/filing/0001558370-23-016871.md","text":"https://secwatch.observer/filing/0001558370-23-016871.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1429260/000155837023016871/0001558370-23-016871-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1429260/000155837023016871/fbio-20231024x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T08:22:22.357579+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}